Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inovio (INO) Upgraded to Buy: Here's Why
Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. ( INO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer Steven Egge - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Felix Ampomah Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call.
Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Conference Call Participants Katherine Degen Presentation Katherine Degen Good morning, and welcome to the H.C.
Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jacqueline E. Shea - CEO, President & Director Jennie Willson - Corporate Participant Investor Relations - Corporate Participant Michael Sumner - Chief Medical Officer Peter D.
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call.
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.
Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
Inovio (INO) Upgraded to Buy: Here's What You Should Know
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Anish Nikhanj - RBC Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
